Cassava Sciences (FLNA) Competitors $1.31 +0.02 (+1.55%) As of 05/22/2026 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FLNA vs. HELP, ALEC, NERV, CHRS, and CNTNShould you buy Cassava Sciences stock or one of its competitors? MarketBeat compares Cassava Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cassava Sciences include Cybin (HELP), Alector (ALEC), Minerva Neurosciences (NERV), Coherus Oncology (CHRS), and Hillstream Biopharma (CNTN). These companies are all part of the "pharmaceutical products" industry. FLNA vs. HELPFLNA vs. ALECFLNA vs. NERVFLNA vs. CHRSFLNA vs. CNTNHow does Cassava Sciences compare to Cybin?Cassava Sciences (NASDAQ:FLNA) and Cybin (NASDAQ:HELP) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings. Does the media favor FLNA or HELP? In the previous week, Cassava Sciences' average media sentiment score of 0.00 equaled Cybin'saverage media sentiment score. Company Overall Sentiment Cassava Sciences Neutral Cybin Neutral Is FLNA or HELP more profitable? Cassava Sciences' return on equity of -53.90% beat Cybin's return on equity.Company Net Margins Return on Equity Return on Assets Cassava SciencesN/A -53.90% -34.20% Cybin N/A -59.98%-50.80% Which has more volatility and risk, FLNA or HELP? Cassava Sciences has a beta of -0.75, indicating that its share price is 175% less volatile than the broader market. Comparatively, Cybin has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Do analysts rate FLNA or HELP? Cybin has a consensus target price of $58.75, indicating a potential upside of 1,155.34%. Given Cybin's stronger consensus rating and higher probable upside, analysts plainly believe Cybin is more favorable than Cassava Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Cybin 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in FLNA or HELP? 38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by company insiders. Comparatively, 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher earnings and valuation, FLNA or HELP? Cybin is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCassava SciencesN/AN/A-$90.97M-$1.61N/ACybinN/AN/A-$81.31M-$4.23N/A SummaryCybin beats Cassava Sciences on 6 of the 11 factors compared between the two stocks.How does Cassava Sciences compare to Alector?Cassava Sciences (NASDAQ:FLNA) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership. Does the media refer more to FLNA or ALEC? In the previous week, Cassava Sciences' average media sentiment score of 0.00 equaled Alector'saverage media sentiment score. Company Overall Sentiment Cassava Sciences Neutral Alector Neutral Which has preferable valuation and earnings, FLNA or ALEC? Cassava Sciences has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCassava SciencesN/AN/A-$90.97M-$1.61N/AAlector$21.05M11.66-$142.93M-$1.19N/A Which has more volatility & risk, FLNA or ALEC? Cassava Sciences has a beta of -0.75, meaning that its share price is 175% less volatile than the broader market. Comparatively, Alector has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Is FLNA or ALEC more profitable? Cassava Sciences has a net margin of 0.00% compared to Alector's net margin of -680.83%. Cassava Sciences' return on equity of -53.90% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets Cassava SciencesN/A -53.90% -34.20% Alector -680.83%-295.17%-40.95% Do analysts recommend FLNA or ALEC? Alector has a consensus target price of $3.63, suggesting a potential upside of 64.03%. Given Alector's stronger consensus rating and higher probable upside, analysts clearly believe Alector is more favorable than Cassava Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Alector 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13 Do institutionals and insiders hold more shares of FLNA or ALEC? 38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by insiders. Comparatively, 8.3% of Alector shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryAlector beats Cassava Sciences on 8 of the 13 factors compared between the two stocks.How does Cassava Sciences compare to Minerva Neurosciences?Minerva Neurosciences (NASDAQ:NERV) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Do analysts recommend NERV or FLNA? Minerva Neurosciences currently has a consensus target price of $10.50, suggesting a potential upside of 99.62%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Minerva Neurosciences is more favorable than Cassava Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has better earnings and valuation, NERV or FLNA? Cassava Sciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMinerva NeurosciencesN/AN/A-$293.42M-$29.16N/ACassava SciencesN/AN/A-$90.97M-$1.61N/A Does the media refer more to NERV or FLNA? In the previous week, Minerva Neurosciences had 11 more articles in the media than Cassava Sciences. MarketBeat recorded 11 mentions for Minerva Neurosciences and 0 mentions for Cassava Sciences. Minerva Neurosciences' average media sentiment score of 0.74 beat Cassava Sciences' score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Overall Sentiment Minerva Neurosciences Positive Cassava Sciences Neutral Do insiders & institutionals have more ownership in NERV or FLNA? 34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 10.4% of Minerva Neurosciences shares are owned by insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, NERV or FLNA? Minerva Neurosciences has a beta of -0.08, meaning that its stock price is 108% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.75, meaning that its stock price is 175% less volatile than the broader market. Is NERV or FLNA more profitable? Minerva Neurosciences' return on equity of 0.00% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Minerva NeurosciencesN/A N/A -32.63% Cassava Sciences N/A -53.90%-34.20% SummaryMinerva Neurosciences beats Cassava Sciences on 10 of the 13 factors compared between the two stocks.How does Cassava Sciences compare to Coherus Oncology?Cassava Sciences (NASDAQ:FLNA) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability. Does the media favor FLNA or CHRS? In the previous week, Cassava Sciences' average media sentiment score of 0.00 equaled Coherus Oncology'saverage media sentiment score. Company Overall Sentiment Cassava Sciences Neutral Coherus Oncology Neutral Which has more risk & volatility, FLNA or CHRS? Cassava Sciences has a beta of -0.75, suggesting that its share price is 175% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Do analysts prefer FLNA or CHRS? Coherus Oncology has a consensus price target of $8.67, suggesting a potential upside of 438.30%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Coherus Oncology is more favorable than Cassava Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is FLNA or CHRS more profitable? Coherus Oncology has a net margin of 397.30% compared to Cassava Sciences' net margin of 0.00%. Cassava Sciences' return on equity of -53.90% beat Coherus Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Cassava SciencesN/A -53.90% -34.20% Coherus Oncology 397.30%-198.90%-46.65% Which has stronger earnings & valuation, FLNA or CHRS? Coherus Oncology has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCassava SciencesN/AN/A-$90.97M-$1.61N/ACoherus Oncology$42.17M5.89$168.02M$1.670.96 Do institutionals and insiders have more ownership in FLNA or CHRS? 38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryCoherus Oncology beats Cassava Sciences on 11 of the 13 factors compared between the two stocks.How does Cassava Sciences compare to Hillstream Biopharma?Cassava Sciences (NASDAQ:FLNA) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability. Does the media favor FLNA or CNTN? In the previous week, Hillstream Biopharma had 2 more articles in the media than Cassava Sciences. MarketBeat recorded 2 mentions for Hillstream Biopharma and 0 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.00 beat Hillstream Biopharma's score of -0.18 indicating that Cassava Sciences is being referred to more favorably in the media. Company Overall Sentiment Cassava Sciences Neutral Hillstream Biopharma Neutral Which has more risk & volatility, FLNA or CNTN? Cassava Sciences has a beta of -0.75, suggesting that its share price is 175% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Do analysts prefer FLNA or CNTN? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is FLNA or CNTN more profitable? Hillstream Biopharma's return on equity of -31.50% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Cassava SciencesN/A -53.90% -34.20% Hillstream Biopharma N/A -31.50%-24.72% Which has stronger earnings & valuation, FLNA or CNTN? Hillstream Biopharma is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCassava SciencesN/AN/A-$90.97M-$1.61N/AHillstream BiopharmaN/AN/A-$35.92M-$1.15N/A Do institutionals and insiders have more ownership in FLNA or CNTN? 38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Comparatively, 6.7% of Hillstream Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryHillstream Biopharma beats Cassava Sciences on 7 of the 10 factors compared between the two stocks. Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for FLNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FLNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FLNA vs. The Competition ExportMetricCassava SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.28M$3.04B$6.44B$12.34BDividend YieldN/A1.97%2.76%5.28%P/E Ratio-0.8118.0421.2625.66Price / SalesN/A336.21552.9986.26Price / CashN/A57.7443.6856.73Price / Book0.935.8610.367.14Net Income-$90.97M$74.99M$3.56B$335.80M7 Day Performance11.02%0.37%5.12%3.02%1 Month Performance-18.63%-2.99%3.54%2.48%1 Year Performance-37.91%34.38%34.14%35.08% Cassava Sciences Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FLNACassava Sciences0.1339 of 5 stars$1.31+1.6%N/A-37.9%$63.28MN/AN/A20HELPCybin3.1209 of 5 stars$4.54-2.8%$58.75+1,194.1%N/A$234.40MN/AN/A50Positive NewsGap UpALECAlector3.0948 of 5 stars$2.11-2.5%$3.63+72.2%+78.2%$233.72M$21.05MN/A270NERVMinerva Neurosciences2.5693 of 5 stars$4.99-4.3%$10.50+110.5%+260.3%$232.34MN/AN/A9Positive NewsAnalyst RevisionGap UpCHRSCoherus Oncology2.5423 of 5 stars$1.51-4.1%$8.67+475.9%+112.9%$232.15M$42.17M0.90330 Related Companies and Tools Related Companies Cybin Competitors Alector Competitors Minerva Neurosciences Competitors Coherus Oncology Competitors Hillstream Biopharma Competitors Whitehawk Therapeutics Competitors Entrada Therapeutics Competitors Tonix Pharmaceuticals Competitors Foghorn Therapeutics Competitors Artiva Biotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FLNA) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
